FibroGen Inc (FGEN) Director Kalevi Kurkijarvi Sells 2,000 Shares of Stock

FibroGen Inc (NASDAQ:FGEN) Director Kalevi Kurkijarvi sold 2,000 shares of the company’s stock in a transaction dated Monday, April 17th. The stock was sold at an average price of $25.25, for a total transaction of $50,500.00. Following the completion of the transaction, the director now owns 38,000 shares in the company, valued at $959,500. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Kalevi Kurkijarvi also recently made the following trade(s):

  • On Thursday, February 16th, Kalevi Kurkijarvi sold 2,000 shares of FibroGen stock. The stock was sold at an average price of $24.45, for a total transaction of $48,900.00.
  • On Thursday, January 19th, Kalevi Kurkijarvi sold 2,000 shares of FibroGen stock. The stock was sold at an average price of $24.90, for a total transaction of $49,800.00.

Shares of FibroGen Inc (NASDAQ:FGEN) traded up 1.94% on Thursday, reaching $26.25. 223,102 shares of the company’s stock traded hands. The firm’s 50 day moving average is $25.12 and its 200 day moving average is $22.40. The firm’s market capitalization is $1.68 billion. FibroGen Inc has a 52 week low of $14.50 and a 52 week high of $27.30.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings results on Wednesday, March 1st. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.53) by $0.01. The business earned $31.91 million during the quarter, compared to analyst estimates of $19.29 million. FibroGen had a negative net margin of 45.93% and a negative return on equity of 40.38%. Analysts expect that FibroGen Inc will post ($2.05) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

ILLEGAL ACTIVITY NOTICE: “FibroGen Inc (FGEN) Director Kalevi Kurkijarvi Sells 2,000 Shares of Stock” was first reported by WKRB News and is the property of of WKRB News. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://www.wkrb13.com/markets/2065248/fibrogen-inc-fgen-director-kalevi-kurkijarvi-sells-2000-shares-of-stock.html.

FGEN has been the topic of a number of research analyst reports. Royal Bank of Canada restated a “buy” rating on shares of FibroGen in a report on Wednesday, January 18th. Stifel Nicolaus restated a “positive” rating and issued a $33.00 price target on shares of FibroGen in a report on Wednesday, January 18th. Finally, Zacks Investment Research upgraded shares of FibroGen from a “hold” rating to a “buy” rating and set a $28.00 price target on the stock in a report on Friday, January 20th. Five equities research analysts have rated the stock with a buy rating, FibroGen has an average rating of “Buy” and a consensus target price of $37.50.

Institutional investors have recently made changes to their positions in the stock. Capital Impact Advisors LLC increased its position in shares of FibroGen by 8.7% in the first quarter. Capital Impact Advisors LLC now owns 46,710 shares of the biopharmaceutical company’s stock worth $1,151,000 after buying an additional 3,727 shares during the period. Teachers Advisors LLC increased its position in shares of FibroGen by 0.9% in the third quarter. Teachers Advisors LLC now owns 445,357 shares of the biopharmaceutical company’s stock worth $9,219,000 after buying an additional 3,790 shares during the period. Sei Investments Co. increased its position in shares of FibroGen by 42.6% in the third quarter. Sei Investments Co. now owns 16,077 shares of the biopharmaceutical company’s stock worth $333,000 after buying an additional 4,805 shares during the period. TLP Group LLC acquired a new position in shares of FibroGen during the third quarter worth about $108,000. Finally, Rothschild Asset Management Inc. increased its position in shares of FibroGen by 4.5% in the third quarter. Rothschild Asset Management Inc. now owns 131,848 shares of the biopharmaceutical company’s stock worth $2,729,000 after buying an additional 5,674 shares during the period. 47.74% of the stock is owned by hedge funds and other institutional investors.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

5 Day Chart for NASDAQ:FGEN

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2065248/fibrogen-inc-fgen-director-kalevi-kurkijarvi-sells-2000-shares-of-stock.html

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.